NCT06973811 (ZR-MTX) is a Phase 2 clinical trial of Methotrexate in Primary Intraocular Lymphoma, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT06973811?

NCT06973811 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT06973811?

Interventions in NCT06973811: Methotrexate, Rituximab (R), Zanubrutinib, Methotrexate (MTX).

What condition does NCT06973811 study?

NCT06973811 studies Primary Intraocular Lymphoma.

Is NCT06973811 still recruiting?

NCT06973811 is currently not yet recruiting. Last updated 20 May 2025.

Last reviewed 2025-05-20 · How we verify

NCT06973811: ZR-MTX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ZR-MTX for PIOL Phase II Trial

Not yet recruiting Phase 2 Last updated 20 May 2025

What this trial tests

Phase 2 trial testing Methotrexate in Primary Intraocular Lymphoma in 47 participants. Not yet recruiting.

Timeline

10 May 2025

Primary endpoint
30 October 2027

30 October 2029

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	47
Start date	10 May 2025
Primary completion	30 October 2027
Estimated completion	30 October 2029
Sites	1 location across China

Drugs / interventions tested

Methotrexate — full drug profile →
Rituximab (R) — full drug profile →
Zanubrutinib (ZANUBRUTINIB) — full drug profile →
Methotrexate (MTX) — full drug profile →

Conditions studied

Primary Intraocular Lymphoma — all drugs for Primary Intraocular Lymphoma →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 75, any sex, with Primary Intraocular Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective single-arm phase II study, with the purpose of evaluating the efficiency of ZR-MTX regimen (Rituximab, Zanubrutinib and methotrexate) combined with intravitreal methotrexate, then followed by minimal residual disease directed Zanubrutinib maintenance in newly-diagnosed primary intraocular lymphoma. The primary endpoint of this study is progression-free survival (PFS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Methotrexate

Trials testing the same drug.

NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant · Phase 1 · withdrawn
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07321912 — Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma · Phase 2 · not yet recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07477691 — Immune Modulation During Palynziq® Treatment in Adults (IMPALA) · Phase 4 · not yet recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06973811 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 20 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06973811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing